Dr. Fatih Kocabas, established Meinox Pharma Technologies as a spin-out company to develop novel personalized therapeutics and commercialize first-in-class MEIS inhibitors.
Assoc. Prof. Dr. Fatih Kocabas received his B.S. degree in Molecular Biology and Genetics from Orta Dogu Technical University and his Ph.D. in Genetics and Development from University of Texas Southwestern Medical Center at Dallas, USA. He developed MEINOX (MEIS, PBX and HOXA9) reporter assays and identified small molecule MEIS inhibitors.
Dr. Kocabas has studied and previously worked at leading universities that are at the top 10 in the world ranking in the field, including California Institute of Technology, University of California San Francisco and Stanford University. He has over 90 proceedings and publications including in very prestigious journals such as Nature, Cell Stem Cell, and Blood. He is the founder and principal investigator of RegBio Research Lab at Yeditepe University. He has secured over 13 research grants from various supporting agencies including TÜBİTAK, BAGEP, THD, ICGEB, EU Marie Curie, MMV Bill & Melinda Gates Foundation, ERA-CVD, Gilead ile Hayat Bulan Fikirler and Gilead Sciences International Hematology and Oncology Program. Dr. Kocabas also has a two-year of drug licensing review commission experience at Turkish Medicines and Medical Devices Agency. Dr. Kocabas has been recently selected as Royal Academy of Engineering Leaders in Innovations Fellow and his business talk selected as one of the best pitch presentation in London, UK.
Web sitesi trafiğini analiz etmek ve web sitesi deneyiminizi optimize etmek amacıyla çerezler kullanıyoruz. Çerez kullanımımızı kabul ettiğinizde, verileriniz tüm diğer kullanıcı verileriyle birlikte derlenir.